TQB2101 for injection

DRUG2 trials

Sponsors

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.

Conditions

Advanced Hematologic MalignanciesBreast CancerColorectal CancerLung Cancer

Phase 1

To Evaluate the Tolerability and Pharmacokinetics of TQB2101 for Injection in Patients With Advanced Malignant Tumors

Not yet recruitingNCT06948539

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Breast Cancer, Colorectal Cancer, Lung Cancer

Start: 2025-04-30End: 2026-12-31Target: 66Updated: 2025-04-29

A Clinical Trial Evaluating TQB2101 in Subjects With Advanced Hematologic Malignancies

RecruitingNCT07113925

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Advanced Hematologic Malignancies

Start: 2025-08-01End: 2028-06-30Target: 114Updated: 2025-08-11